Search

In Stock

Buy Onivyde (irinotecan hydrochloride trihydrate) Online

DISEASE INDICATIONS: Pancreatic Cancer

MANUFACTURER: Baxalta Innovations GmbH

USAGE: Intravenous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Health Canada

Therapeutic Goods Administration (TGA)

Medsafe (NZ)

Onivyde (irinotecan hydrochloride trihydrate) is a potent and specialized anti-cancer medication used in the treatment of certain types of advanced or metastatic cancers. This chemotherapy drug belongs to a class of medications known as topoisomerase I inhibitors and is specifically indicated for patients with metastatic adenocarcinoma of the pancreas after previous therapy has failed.

$1,010.33

Clear
Compare
SKU:844972

Onivyde (irinotecan hydrochloride trihydrate) is a potent and specialized anti-cancer medication used in the treatment of certain types of advanced or metastatic cancers. This chemotherapy drug belongs to a class of medications known as topoisomerase I inhibitors and is specifically indicated for patients with metastatic adenocarcinoma of the pancreas after previous therapy has failed.

Key features and characteristics of Onivyde include:

  1. Active Ingredient: The active ingredient in Onivyde is irinotecan hydrochloride trihydrate, which is a water-soluble form of irinotecan.
  2. Mechanism of Action: Onivyde exerts its anti-cancer effects by interfering with the replication and transcription of DNA within cancer cells. It works by inhibiting topoisomerase I, an enzyme responsible for unwinding and repairing DNA. By blocking this enzyme, Onivyde causes DNA damage and prevents the cancer cells from dividing and growing.
  3. Indications: Onivyde is primarily used for the treatment of metastatic adenocarcinoma of the pancreas that has progressed after prior gemcitabine-based chemotherapy. It is not typically used as a first-line treatment for pancreatic cancer.
  4. Administration: Onivyde is administered intravenously (IV) by a healthcare professional in a clinical setting such as a hospital or infusion center. The dosing regimen and schedule may vary depending on the individual patient and the specific cancer being treated.
  5. Adverse Effects: Like many chemotherapy drugs, Onivyde may cause a range of side effects, including nausea, vomiting, diarrhea, fatigue, and a decreased white blood cell count (neutropenia), which can increase the risk of infection. Patients receiving Onivyde are closely monitored for these and other potential side effects.
  6. Special Precautions: Onivyde should only be used under the supervision of an experienced oncologist. It may not be suitable for all patients, and its use should be carefully considered in light of the potential benefits and risks.
  7. Combination Therapy: Onivyde is sometimes used in combination with other chemotherapy agents or supportive medications to enhance its effectiveness and manage side effects.
  8. Patient Education: Patients receiving Onivyde should be educated about the potential side effects, the importance of regular follow-up appointments, and the need for diligent monitoring during treatment.
  9. Research and Clinical Trials: As of my last knowledge update in September 2021, Onivyde had been the subject of ongoing research and clinical trials to explore its efficacy in different cancer types and treatment settings. New developments and indications may have emerged since then.

It’s important to note that medical information can evolve, and the latest guidance on Onivyde should be obtained from a healthcare provider or a reliable medical source, as there may have been updates or changes in its use or availability after my last knowledge update.

Package

1 vial of 50 mg/10 mL

Reviews

There are no reviews yet.

Write a review

Your email address will not be published. Required fields are marked *

Bestsellers

Buy Rydapt (midostaurin) Online

$14,303.19
(0 Reviews)
DISEASE INDICATIONS: Leukemia MANUFACTURER: Novartis Europharm Limited USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Therapeutic Goods Administration (TGA) Medsafe (NZ) Rydapt is a groundbreaking medication, primarily used in combination with standard chemotherapy for newly diagnosed AML patients who have a specific genetic mutation known as FLT3 mutation.

Buy Rubraca (rucaparib) Online

From $1,647.81
(0 Reviews)
DISEASE INDICATIONS: Gynaecological Cancer MANUFACTURER: Clovis Oncology, Inc. USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Rubraca is indicated for the treatment of women with advanced ovarian cancer who have received two or more prior lines of chemotherapy and have a deleterious BRCA mutation, as detected by an FDA-approved test.

Buy Portrazza (necitumumab) Online

$7,535.16
(0 Reviews)
DISEASE INDICATIONS: Lung Cancer MANUFACTURER: Eli Lilly Nederland B.V. USAGE: Intravenous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Portrazza, with its generic name Necitumumab, is a monoclonal antibody developed by Eli Lilly and Company. It received approval from the United States Food and Drug Administration (FDA) in late 2015, marking a significant advancement in the treatment of advanced squamous NSCLC.

Buy Onivyde (irinotecan hydrochloride trihydrate) Online

$1,010.33
(0 Reviews)
DISEASE INDICATIONS: Pancreatic Cancer MANUFACTURER: Baxalta Innovations GmbH USAGE: Intravenous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Therapeutic Goods Administration (TGA) Medsafe (NZ) Onivyde (irinotecan hydrochloride trihydrate) is a potent and specialized anti-cancer medication used in the treatment of certain types of advanced or metastatic cancers. This chemotherapy drug belongs to a class of medications known as topoisomerase I inhibitors and is specifically indicated for patients with metastatic adenocarcinoma of the pancreas after previous therapy has failed.

Buy Odomzo (sonidegib) Online

$5,335.57
(0 Reviews)
DISEASE INDICATIONS: Skin Cancer MANUFACTURER: Sun Pharmaceutical Industries Europe B.V. USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Therapeutic Goods Administration (TGA) Odomzo, also known by its generic name Sonidegib, is a remarkable medication that has ushered in new hope for individuals grappling with the challenges of Advanced Basal Cell Carcinoma (BCC), a type of skin cancer that can be both disfiguring and debilitating.

Buy Ninlaro (ixazomib) Online

$5,829.49
(0 Reviews)
DISEASE INDICATIONS: Multiple Myeloma MANUFACTURER: Takeda Pharma A/S USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Pharmaceuticals and Medical Devices Agency (PMDA) Therapeutic Goods Administration (TGA) Ninlaro, also known by its generic name Ixazomib, is a medication that has become a beacon of hope for individuals facing the relentless challenges of Multiple Myeloma (MM), a complex and incurable cancer of the plasma cells in the bone marrow.

Buy Tagrisso (Osimertinib) Online

$5,571.28
(0 Reviews)
DISEASE INDICATIONS: Lung Cancer MANUFACTURER: AstraZeneca AB USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Therapeutic Goods Administration (TGA) Medsafe (NZ) Tagrisso has been a game-changer, specifically targeting EGFR (epidermal growth factor receptor) mutations, which are prevalent in a subset of NSCLC patients.

Back to Top
Product has been added to your cart